BEFORE it is visible
SCROLL DOWN OR USE ▼▲ KEYS TO LEARN MORE
Detection mistakes can kill
Skin Cancer is the most common cancer globally
24 million advanced diagnostics
5 million excisions
In the US alone, each year:
new lethal skin cancer cases
Early detection is the key factor
*American Academy of Dermatology (5 year survival rates data)
Early detection Melanoma survival rates are 98%
Dropping down to 15% if NOT detected in time
We have developed a revolutionary device*
Early detection of skin-cancer just became a matter of point & click. An optic device that could be used professionally as well as at home to provide real-time valuable scanning for early skin-cancer detection
*NOTE: Scade-Medical solutions are not yet cleared for clinical use until FDA approval is obtained
Decision Supporting Dermatoscope*
MelAssure and MoleMark are diagnostic tools designed for use by dermatologists in clinics and operating rooms (OR) providing real-time information, which until now has been beyond the reach of doctors.
Compared with other companies trying to detect primarily color changes, Scade-Medical breakthrough technology is capable to follow the underlying skin distortions beyond the visual range. Since skin distortions precede pigmentation changes our solution can dramatically increase the likelihood of life-saving early detection of skin-cancer.
*NOTE: MelAssure and MoleMark are not cleared for clinical use until FDA approval is obtained
Our solutions are designed to help detect and define skin cancer at its early stage, even when no visual indication exists, thus dramatically increasing detection rates, decreasing mortality, helping avoid recurring excisions and with lower false-positives - decreasing unnecessary scarring.
Achieved 100% accuracy in a recent clinical study, successfully marking as ‘Suspicious’ all cancerous lesions also defined as such by the pathologist, and nearly 92% identification success rate for lesions suspected of malignant melanoma (comparing to 1%-6% with other detection techniques)
Internal preliminary clinical studies, conducted in Ben-Gurion University of the Negev, proved exceptionally high (over 90%) correlations between device and histology results in over 70 skin lesions.
Multi-region patents filed, PCT/IB2012/050444 ("OPTICAL POLARIMETRIC IMAGING"), already approved in Australia & New-Zealand
We help to protect our way of life
The non-lethal skin cancer takes about 3,000,000 people worldwide by surprise each year